论文部分内容阅读
应用格拉诺赛特预防和治疗化疗引起的白细胞减少。方法：预防用药组：末次化疗结束４８～７２小时给格拉诺赛特５０～１００μｇ，皮下，ｑｄ，５～１４天；治疗组在白细胞计数低于３０×１０９／Ｌ后给格拉诺赛特１００～２００μｇ，皮下，ｑｄ，５～１４天。结果：预防用药组５４个周期白细胞计数均在４０×１０９／Ｌ以上，占７５％（５４／７２）；１８个周期白细胞计数低至（１８～３９）×１０９／Ｌ之间，占２５％（１８／７２），但持续时间不超过５天，均不影响下一周期化疗的实施。治疗组给格拉诺赛特前白细胞计数平均１６×１０９／Ｌ，治疗平均５２天后白细胞计数上升至４０×１０９／Ｌ以上。结论：格拉诺赛特是预防和治疗化疗引起的白细胞减少的有效药物。
Application of Granolette for prevention and treatment of chemotherapy-induced leukopenia. Methods: Prophylaxis group: 50 to 100 μg GranoSite for 48 to 72 hours after the end of the last chemotherapy, subcutaneously, qd, for 5 to 14 days; the treatment group gave Granoise at a white blood cell count of less than 30×109/L. Special 100 ~ 200μg, subcutaneous, qd, 5 ~ 14 days. RESULTS: The white blood cell counts of 54 prophylaxis groups were all above 40×109/L, accounting for 75% (54/72); the white blood cell counts of 18 cycles were as low as (18～39)×109/L. Between, 25% (18/72), but the duration does not exceed 5 days, do not affect the implementation of the next cycle of chemotherapy. In the treatment group, the average white blood cell count before Granosite was 16×109/L, and after 5治疗2 days, the white blood cell count increased to 40×109/L. Conclusion: Granolette is an effective drug for preventing and treating chemotherapy-induced leukopenia.